| Name | Title | Contact Details |
|---|
Why we`re excited: The mission for Payformance Solutions is simple. We aim to be a catalyst for payment transformation in the healthcare industry. Our proprietary software solutions allow payers and providers to focus on what really matters: providing patients with access to care that yields the best health outcomes, at the lowest costs. The healthcare industry is complex and fragmented. Payers and providers are faced with a lack of transparency and conflicting financial goals that fail to consider the health outcomes of patients. Payformance offers data-driven, turnkey software solutions that provide payers and providers with the technical tools and resources needed to design, evaluate, build, measure, and negotiate value-based reimbursement contracts — as a neutral third party. Our holistic solutions allow payers and providers to collaborate in an ecosystem that aligns financial goals with patient outcomes. Not to boast, but a little bit about us: Payformance Solutions is a health-tech company dedicated to advancing payment transformation in the healthcare industry. We are a wholly owned subsidiary of Altarum Institute, a nonprofit systems research and consulting organization that has been servicing government and private sector clients since 1946. Altarum Institute, as a non-profit, ensures that the public interest is always preeminent in client work. Our dedication to social responsibility is evident in all that we do, serving the public good with integrity and enabling others to do the same. Altarum develops and promotes best practices in the application of information technology to health and health care. Applying systems research principles and analytic objectivity, we work to increase access to health information; improve the organization and usability of health information; and develop new knowledge from health information.
United Hospital is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Canadian Aboriginal AIDS Network is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.